Clinical Research Directory
Browse clinical research sites, groups, and studies.
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
Sponsor: M.D. Anderson Cancer Center
Summary
This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Extramedullary myeloid leukemia is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. Diagnostic procedures, such as PET/MRI, 18F-FDG PET/CT and whole body MRI, may help find and diagnose extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.
Official title: PET/MR, PET/CT and Whole Body MR in Newly Diagnosed Acute Myeloid Leukemia (AML)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
77
Start Date
2020-07-15
Completion Date
2027-09-15
Last Updated
2025-11-03
Healthy Volunteers
No
Interventions
Computed Tomography
Undergo 18F-FDG PET/CT
Diffusion Weighted Imaging
Undergo whole body PET/MRI
Fludeoxyglucose F-18
Undergo 18F-FDG PET/CT
Gadolinium
Given IV
Magnetic Resonance Imaging
Undergo whole body PET/MRI
Positron Emission Tomography
Undergo 18F-FDG PET/CT and whole body PET/MRI
Three-Dimensional Spoiled Gradient MRI
Undergo whole body PET/MRI
Locations (1)
M D Anderson Cancer Center
Houston, Texas, United States